为尤因肉瘤构建EWS-FLI1驱动的转基因小鼠模型面临的挑战。
Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.
作者信息
Ramachandran Balaji, Rajkumar Thangarajan, Gopisetty Gopal
机构信息
Department of Molecular Oncology, Cancer Institute (W.I.A) No. 38, Sardar Patel Road, Adyar, Chennai 600036, India.
出版信息
Am J Transl Res. 2021 Nov 15;13(11):12181-12194. eCollection 2021.
Abstract
EWS-FLI1 is a master regulator of Ewing sarcoma (ES) oncogenesis. Although EWS-FLI1 represents a clear therapeutic target, targeted therapeutic inhibitors are lacking. Scientific literature has indicated accumulating information pertaining to EWS-FLI1 translocation, pathogenesis, function, oncogenic partnerships, and potential clinical relevance. However, attempts to develop EWS-FLI1-driven human-like ES mouse models or in systems ended up with limited success. Establishing such models as preclinical screening tools may accelerate the development of EWS-FLI1 targeted therapeutic inhibitors. This review summarizes the current scenario, which focuses on the limitations, challenges, and possible reasons for past failures in model development and also plausible alternatives.
摘要
EWS-FLI1是尤因肉瘤（ES）肿瘤发生的主要调节因子。尽管EWS-FLI1是一个明确的治疗靶点，但缺乏靶向治疗抑制剂。科学文献表明，有关EWS-FLI1易位、发病机制、功能、致癌伙伴关系及潜在临床相关性的信息不断积累。然而，尝试开发由EWS-FLI1驱动的类人ES小鼠模型或体外系统，最终取得的成功有限。建立此类模型作为临床前筛选工具可能会加速EWS-FLI1靶向治疗抑制剂的开发。本综述总结了当前的情况，重点关注模型开发中过去失败的局限性、挑战和可能原因，以及合理的替代方案。
相似文献
1
Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.为尤因肉瘤构建EWS-FLI1驱动的转基因小鼠模型面临的挑战。
Am J Transl Res. 2021 Nov 15;13(11):12181-12194. eCollection 2021.
2
High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.尤因肉瘤细胞中的高通量RNA干扰筛选确定富含亮氨酸重复序列和WD重复结构域1（LRWD1）是EWS-FLI1驱动的细胞活力的调节因子。
Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.
3
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.六个独立实验室尝试创建尤文肉瘤小鼠模型的综合经验。
Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.
4
BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.BET溴结构域抑制剂可抑制尤因肉瘤中EWS-FLI1依赖的转录及IGF1自分泌机制。
Oncotarget. 2016 Jul 12;7(28):43504-43517. doi: 10.18632/oncotarget.9762.
5
EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.EWS-FLI1 通过与 Foxq1 合作在小鼠尤文肉瘤中调节转录程序。
Cancer Sci. 2018 Sep;109(9):2907-2918. doi: 10.1111/cas.13710. Epub 2018 Jul 18.
6
Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.长链非编码RNA EWSAT1介导的基因抑制促进尤因肉瘤的肿瘤发生。
J Clin Invest. 2014 Dec;124(12):5275-90. doi: 10.1172/JCI72124. Epub 2014 Nov 17.
7
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.SLFN11是EWS-FLI1的转录靶点，也是尤因肉瘤药物反应的决定因素。
Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.
8
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.尤文肉瘤中涉及 IGF 通路靶向的新型致癌机制，由 EWS/Fli1 调节的 microRNAs 介导。
Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.
9
Slit2 signaling stimulates Ewing sarcoma growth.Slit2信号传导刺激尤因肉瘤生长。
Genes Cancer. 2022 Dec 14;13:88-99. doi: 10.18632/genesandcancer.227. eCollection 2022.
10
Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.阻断道路、停止引擎还是杀死司机？靶向尤文肉瘤中 EWS/FLI-1 融合作为新型治疗方法的进展。
Expert Opin Ther Targets. 2014 Nov;18(11):1315-28. doi: 10.1517/14728222.2014.947963. Epub 2014 Aug 27.
引用本文的文献
1
Ubiquitin-specific protease 6 (USP6) mRNA lipid nanoparticles ignite anti-tumor immunity and suppress tumorigenesis in Ewing sarcoma.泛素特异性蛋白酶6（USP6）信使核糖核酸脂质纳米颗粒激发尤因肉瘤的抗肿瘤免疫并抑制肿瘤发生。
Mol Cancer Ther. 2025 Jun 25. doi: 10.1158/1535-7163.MCT-24-0173.
2
Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets.在EWS-FLI驱动的尤因肉瘤中可成药的上调蛋白作为新出现的治疗靶点。
Am J Transl Res. 2025 Mar 15;17(3):1580-1603. doi: 10.62347/YMEU1808. eCollection 2025.
3
YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells.YAP1是在胰岛素样生长因子-1（IGF-1）介导的骨间充质干细胞重编程过程中，EWS::FLI1依赖性恶性转化的关键调节因子。
Cell Rep. 2025 Mar 25;44(3):115381. doi: 10.1016/j.celrep.2025.115381. Epub 2025 Mar 12.
4
Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids.具有更高生理相关性的优化培养条件揭示了尤因肉瘤球体中癌基因依赖性代谢特征。
Cell Rep Methods. 2025 Feb 24;5(2):100966. doi: 10.1016/j.crmeth.2025.100966. Epub 2025 Feb 7.
5
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma.曲贝替定在骨肉瘤模型中可提高溶瘤病毒的抗肿瘤疗效、病毒基因表达及免疫效应功能。
Mol Ther Oncol. 2024 Sep 26;32(4):200886. doi: 10.1016/j.omton.2024.200886. eCollection 2024 Dec 19.
6
Preclinical models for the study of pediatric solid tumors: focus on bone sarcomas.用于小儿实体瘤研究的临床前模型：聚焦骨肉瘤
Front Oncol. 2024 Jul 18;14:1388484. doi: 10.3389/fonc.2024.1388484. eCollection 2024.
7
Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.条件性等位基因中 CIC::DUX4 融合癌蛋白的自发表达可强力驱动基因工程小鼠中的肉瘤形成。
Oncogene. 2024 Apr;43(16):1223-1230. doi: 10.1038/s41388-024-02984-8. Epub 2024 Feb 27.
8
Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models.在基因工程小鼠模型中，CIC-DUX4融合癌蛋白的表达模拟了人类CIC重排肉瘤。
Res Sq. 2023 Oct 29:rs.3.rs-3487637. doi: 10.21203/rs.3.rs-3487637/v1.
9
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.新兴的癌症治疗策略：克服不可成药蛋白。
Int J Biol Sci. 2023 Jun 26;19(11):3360-3382. doi: 10.7150/ijbs.83026. eCollection 2023.
本文引用的文献
1
Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis.EWSR1-FLI1 融合癌基因在胰腺细胞中的表达导致胰腺萎缩和脂肪化生。
Pancreatology. 2020 Dec;20(8):1673-1681. doi: 10.1016/j.pan.2020.10.033. Epub 2020 Oct 10.
2
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer.局部和循环中的SOX9作为原发性骨癌诊断的潜在生物标志物。
J Bone Oncol. 2020 May 31;23:100300. doi: 10.1016/j.jbo.2020.100300. eCollection 2020 Aug.
3
Wnt/β-catenin-activated Ewing sarcoma cells promote the angiogenic switch.Wnt/β-catenin 激活的尤文肉瘤细胞促进血管生成开关。
JCI Insight. 2020 Jul 9;5(13):135188. doi: 10.1172/jci.insight.135188.
4
Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma.致癌基因劫持发育转录因子导致尤文肉瘤对氧化应激敏感。
Nat Commun. 2020 May 15;11(1):2423. doi: 10.1038/s41467-020-16244-2.
5
Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.Stag2 缺失与 EWS-FLI1 协同作用，转化小鼠间充质干细胞。
BMC Cancer. 2020 Jan 2;20(1):3. doi: 10.1186/s12885-019-6465-8.
6
The Fusion Oncogene FUS-CHOP Drives Sarcomagenesis of High-Grade Spindle Cell Sarcomas in Mice.融合癌基因FUS-CHOP驱动小鼠高级别梭形细胞肉瘤的肉瘤发生。
Sarcoma. 2019 Jul 25;2019:1340261. doi: 10.1155/2019/1340261. eCollection 2019.
7
CD151 confers metastatic potential to clear cell sarcoma of the soft tissue in animal model.在动物模型中，CD151赋予软组织透明细胞肉瘤转移潜能。
Oncol Lett. 2019 Jun;17(6):4811-4818. doi: 10.3892/ol.2019.10164. Epub 2019 Mar 19.
8
Anatomic Origin of Osteochondrogenic Progenitors Impacts Sensitivity to EWS-FLI1-Induced Transformation.骨软骨祖细胞的解剖学起源影响对EWS-FLI1诱导转化的敏感性。
Cancers (Basel). 2019 Mar 6;11(3):313. doi: 10.3390/cancers11030313.
9
Insight into the Etiology of Undifferentiated Soft Tissue Sarcomas from a Novel Mouse Model.从新型小鼠模型深入了解未分化软组织肉瘤的病因。
Mol Cancer Res. 2019 May;17(5):1024-1035. doi: 10.1158/1541-7786.MCR-18-0117. Epub 2019 Jan 25.
10
FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer.FusionPathway：预测癌症中基因融合相关的通路和治疗靶点。
PLoS Comput Biol. 2018 Jul 24;14(7):e1006266. doi: 10.1371/journal.pcbi.1006266. eCollection 2018 Jul.
Zotero 插件